AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06594068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE (Furie 2017). Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo (Furie 2019; Morand 2020). Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo (Furie 2017). These data resulted with applications to the FDA and the EMA, leading to approval by them in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
Study NCT04840875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell treatment
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
Study NCT05077917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
Study NCT05077917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
Study NCT06449183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIDAS® TBI Test [GFAP and UCH-L1 assays]
Description: The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
Study NCT05407753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
Study NCT05407753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
Study NCT06158438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-754-4 Treatment
Description: Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
Study NCT04763161 — intervention group
Intervention type: PROCEDURE
Intervention: Decompressive hemicraniectomy
Description: Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
Study NCT04763161 — intervention group
Intervention type: PROCEDURE
Intervention: neurosurgical operation
Description: neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
Study NCT06455358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 61Cu-NODAGA-LM3
Description: Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
Study NCT06455358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
Study NCT06149273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep School
Description: Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
Study NCT06149273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Oral and written information about improving sleep habits given by an educated nurse.
Study NCT06299150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPS e.max CAD
Description: CAD CAM Restoration
Study NCT06299150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max CAD
Description: CAD CAM Restoration
Study NCT05365295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRM (Deese, Roediger et McDermott task)
Description: Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes.
Study NCT05232591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The teeth diagnosed with chronic apical periodontitis
Description: GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
Study NCT06589518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Citrate
Description: Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
Study NCT06675305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice (James White, UK)
Description: One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
Study NCT06675305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acute supplementation (James White, UK)
Description: One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
Study NCT06689813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D tablets
Description: Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
Study NCT06689813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ispaghula husk
Description: Ispaghula husk tablets were given to Group B participants
Study NCT06688877 — intervention group
Intervention type: DEVICE
Intervention: headphones with activated noise cancelling
Description: noise cancelling is new
Study NCT05567666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume Catheter System
Description: Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
Study NCT05761080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin clavulanic acid IV during hospitalization
Description: Amoxicillin clavulanic acid IV 5 days during hospitalization. Application of discharge criteria at 5 postoperative days, according to guidelines current clinic.
Study NCT06688877 — intervention group
Intervention type: DEVICE
Intervention: headphones with activated noise cancelling and soft 60 bpm musc
Description: noise cancelling is new
Study NCT06688877 — intervention group
Intervention type: DEVICE
Intervention: heart rate measurement
Description: three times (before, during and after surgery)
Study NCT05761080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanic acid IV 3 days and PO until day 5
Description: Amoxicillin clavulanic acid IV 3 days during hospitalization and at discharge Amoxicillin clavulanic acid PO until day 5.~Application of discharge criteria at 72 postoperative hours, administering oral antibiotic therapy with a spectrum similar to that of the control group total of 5 days and sending the patient home with oral analgesia.
Study NCT06688877 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: two times (before and after surgery)
Study NCT05970939 — intervention group
Intervention type: OTHER
Intervention: Development of the Telerehabilitation Usability Questionnaire
Description: This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
Study NCT05612750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
Study NCT05612750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
Study NCT06081101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection
Description: Medication will be injected into SI joint under ultrasound guidance
Study NCT06081101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection
Description: Medication will be injected into SI joint under ultrasound guidance
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
Study NCT05678595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
Study NCT05678595 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
Study NCT05678595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
Study NCT06475339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
Study NCT05678595 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
Study NCT06623721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Movement-evoked transcutaneous auricular Vagus nerve stimulation
Description: Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur.
Study NCT05185440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
Study NCT05185440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
Study NCT05185440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
Study NCT05185440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Scripts
Description: scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
Study NCT04315649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D movie viewing
Description: 3D movie viewing
Study NCT05005156 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Description: All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
Study NCT05005156 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Description: All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
Study NCT05071781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotropin-release hormone
Description: intravenous CRH (100 µg)
Study NCT05071781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticotropin-release hormone
Description: intravenous CRH (100 µg)
Study NCT05071781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotropin-release hormone
Description: a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
Study NCT05071781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticotropin-release hormone
Description: a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
Study NCT06694051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: marking
Description: axis marking
Study NCT06689800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get REAL
Description: Family health communication tool
Study NCT06622889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Intervention Program
Description: The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.
Study NCT05031325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection with Purastat
Description: Purastat (peptidic gel) application
Study NCT06361238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
Study NCT06361238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Study NCT06693531 — intervention group
Intervention type: DRUG
Intervention: dupilumab
Description: No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
Study NCT06709274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg daily, for EGFR-positive patients
Study NCT06709274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600mg BID, for ALK-rearranged patients
Study NCT06709274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
Study NCT04680936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: low dose dextrose solution
Study NCT04680936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 15 % in Water
Description: high dose dextrose solution
Study NCT04680936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: isotonic saline solution
Study NCT06258811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel, cispatin, tislelizumab
Description: Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
Study NCT04936451 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours.